Zura Bio Limited (ZURA)
| Market Cap | 521.54M +645.9% |
| Revenue (ttm) | n/a |
| Net Income | -106.13M |
| EPS | -1.07 |
| Shares Out | 95.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,174,194 |
| Open | 5.07 |
| Previous Close | 5.08 |
| Day's Range | 5.01 - 5.52 |
| 52-Week Range | 1.08 - 7.44 |
| Beta | -0.03 |
| Analysts | Strong Buy |
| Price Target | 15.67 (+185.43%) |
| Earnings Date | Aug 13, 2026 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ZURA stock is "Strong Buy." The 12-month stock price target is $15.67, which is an increase of 185.43% from the latest price.
News
Zura Bio initiated with an Outperform at William Blair
William Blair initiated coverage of Zura Bio (ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two…
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Zura Bio exceeds enrollment target in HS, SSc Phase 2 studies
Zura Bio (ZURA) announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target…
Zura Bio sees cash runway through the end of 2028
Cash and cash equivalents were $225.6M as of March 31, 2026. Consistent with prior guidance and inclusive of the planned third-indication study, Zura continues to expect its existing cash to…
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Zura Bio Proxy statement: Proxy filing
Zura Bio filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improv...
Zura Bio names Muzammil Mustufa chief business officer
Zura Bio (ZURA) announced the appointment of Muzammil Mustufa as Chief Business Officer. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations effo...
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio reports Q1 EPS (22c) vs (19c) last year
“We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing conviction in bispecific approaches and increased appreciation for IL-17 and BAFF biology” sa...
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio Quarterly report: Q1 2026
Zura Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zura Bio Earnings release: Q1 2026
Zura Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Zura Bio Proxy statement: Proxy filing
Zura Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Zura Bio management to meet virtually with Clear Street
Virtual Meeting to be held on April 23 hosted by Clear Street.
Zura Bio management to meet with Piper Sandler
Meeting to be held in Boston on March 30-31 hosted by Piper Sandler.
Zura Bio price target lowered to $15 from $16 at Oppenheimer
Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $15 from $16 and keeps an Outperform rating on the shares after the company reported year-end financial results and…
Zura Bio reports FY25 EPS ($1.06) vs (60c) last year
“2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and a disciplined focus on advancing our clinical strategy,” said Sandeep Kulkarni,…
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully imp...
Zura Bio Annual report: Q4 2025
Zura Bio has published its Q4 2025 annual report on March 19, 2026.
Zura Bio Earnings release: Q4 2025
Zura Bio released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Zura Bio Transcript: Leerink Global Healthcare Conference 2026
The company is prioritizing tibulizumab, a first-in-class bispecific antibody targeting IL-17 and BAFF, with pivotal phase II data in hidradenitis suppurativa expected in Q4 and systemic sclerosis data in the first half of 2027. Strategic focus is on robust trial design, market differentiation, and readiness for phase III advancement.